Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.080
-0.160 (-7.14%)
At close: Mar 6, 2026, 4:00 PM EST
2.110
+0.030 (1.44%)
After-hours: Mar 6, 2026, 7:49 PM EST
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$3,024,176
Market Cap
10.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| Longeveron | 25 |
| Soligenix | 16 |
| CalciMedica | 15 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
| Akari Therapeutics, | 9 |
MBRX News
- 16 days ago - Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - GlobeNewsWire
- 17 days ago - Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewsWire
- 18 days ago - Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - GlobeNewsWire
- 22 days ago - Moleculin Launches CEO Corner Platform to Share Strategic Insights - GlobeNewsWire
- 4 weeks ago - Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 7 weeks ago - Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - GlobeNewsWire
- 7 weeks ago - Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - GlobeNewsWire
- 2 months ago - Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors - GlobeNewsWire